Crossmark

Hyperparathyroidism in patients with low bone mineral density treated with zoledronic acid or denosumab

Crossref DOI link: https://doi.org/10.1016/j.medcle.2024.07.014

Published Print: 2024-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Riesco-Bárcena, Carmen

Ivorra-Cortés, José

Grau-García, Elena

González-Puig, Luis

Leal, Samuel

Huaylla, Anderson

Román-Ivorra, José
License Information

Text and Data Mining valid from 2024-12-01

Text and Data Mining valid from 2024-12-01

stm-asf valid from 2024-12-01

stm-asf valid from 2024-12-01

stm-asf valid from 2024-12-01

stm-asf valid from 2024-12-01

stm-asf valid from 2024-12-01
More Information

This article is maintained by: Elsevier

Article Title: Hyperparathyroidism in patients with low bone mineral density treated with zoledronic acid or denosumab

Journal Title: Medicina Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcle.2024.07.014

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.medcli.2024.07.020

Content Type: article

Copyright: © 2024 Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.